TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A WEHI-led study published in Cancer Cell identified gamma delta T cells in small cell lung cancer and found they could kill cancer cells in patient-derived laboratory tumor models. Tarlatamab and zoledronate strengthened this response in experiments, but the findings have not yet shown that the approach benefits patients in clinical trials.
Researchers at WEHI have identified gamma delta T cells that can recognize and kill small cell lung cancer in laboratory models, a finding that may offer another route for targeting a cancer that often evades conventional immune defenses. The study, published in Cancer Cell, also found that tarlatamab and zoledronate strengthened the cells’ cancer-fighting activity in experiments; whether the approach improves outcomes for patients remains untested.
The researchers studied miniature tumors grown in the laboratory from tissue donated by patients with small cell lung cancer. They introduced gamma delta T cells collected from the same patients’ blood into the models and observed the cells identifying and destroying cancer cells. The samples came through the Victorian Cancer Biobank in partnership with the Royal Melbourne Hospital.
The team then tested two medicines already used for other purposes. In the experiments, zoledronate increased the number of gamma delta T cells available and improved their ability to identify tumors. Tarlatamab, a treatment approved for small cell lung cancer, helped bring the immune cells and cancer cells together. Using the drugs together substantially increased cancer-cell killing in the laboratory models, according to the study report.
The researchers also reported that patients whose tumors contained more gamma delta T cells tended to have longer survival. That is an association in patient data, not evidence that the cells caused longer survival or that increasing their numbers would extend life. The report does not provide a clinical trial result showing that the drug combination or cell-based approach is safe and effective for patients.
A Different Route to Target SCLC
Small cell lung cancer is difficult to treat in part because tumors can avoid detection by conventional immune cells used by many immunotherapy approaches. The reported findings point to a possible alternative: gamma delta T cells may detect and attack tumors that escape those other immune defenses. If confirmed in patients, that could matter for a disease where lasting benefit from immunotherapy has been limited.
The study also connects the laboratory finding to possible treatment strategies. The researchers say the results could inform adoptive cell transfer, in which immune cells are collected, expanded outside the body and returned to the patient. Since methods to expand and reinfuse gamma delta T cells already exist, the team argues the work could support further development. That is a research possibility, not an available new treatment based on this study.
The report describes small cell lung cancer as among the deadliest cancers and says fewer than 7% of patients survive five years after diagnosis. The finding is therefore relevant because it identifies a candidate immune pathway and suggests ways to test it, not because it has yet changed care.
small cell lung cancer patient guide book
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How the Team Tested the Cells
Small cell lung cancer, or SCLC, is known for its ability to escape immune surveillance. The ScienceDaily report says immunotherapy has produced lasting benefits for only a small proportion of people with this cancer, despite advances in other cancer types. That gap is the problem the WEHI team set out to address.
Rather than relying only on conventional immune cells, the researchers focused on gamma delta T cells, a less-studied immune-cell population. They used patient-derived miniature tumors to examine whether the cells could attack SCLC directly, then tested whether existing medicines could strengthen the response. These models allow experiments on patient tissue but do not reproduce every feature of a person’s disease or establish how a treatment will work in the body.
Dr. Jin Ng, the study’s first author, said the results could also support work on cell-transfer therapies. The study’s senior author, Professor Kate Sutherland, described the work as evidence that these cells may provide an alternative immune attack route. Both statements reflect the researchers’ interpretation of the findings; the central reported experiments were conducted in laboratory tumor models.
“For decades, we’ve known that small cell lung cancer is exceptionally good at hiding from the immune system. We’ve found an immune cell that appears to be able to see through that disguise.”
— Professor Kate Sutherland, study senior author and WEHI laboratory head
lung cancer caregiver support journal
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Patient Benefits Remain Unproven
The main evidence described is from laboratory experiments using patient-derived tumor models, alongside an association between tumor gamma delta T-cell levels and survival. It remains unclear whether the approach works in patients, what dose or schedule would be appropriate, and whether combining the medicines with gamma delta T-cell treatment would be safe or improve outcomes.
The available report also does not specify a clinical trial timeline, the number of patients represented in the survival analysis, or how the approach might compare with current treatment options. The finding that patients with more of these cells tended to live longer does not establish that the cells caused the difference; other factors could contribute.
Although tarlatamab is described as an approved SCLC treatment and zoledronate is used for other conditions, their experimental combination to strengthen gamma delta T-cell activity is not established here as a treatment regimen. Further research is needed before any conclusions about patient care can be made.
lung cancer treatment appointment organizer
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Clinical Testing Is the Next Step
The immediate next step is to determine whether the laboratory findings can be reproduced and translated into studies involving patients. Researchers would need to test the safety and activity of the medicines and cell-based strategies in clinical settings, and identify which patients, if any, might benefit. The source report does not announce a trial or give a start date.
The team’s findings may guide further work on expanding gamma delta T cells and returning them to patients, as well as on whether zoledronate or tarlatamab can support that response. Until clinical results are available, the discovery should be understood as a promising preclinical finding, not a new treatment recommendation.
Key Questions
What are gamma delta T cells?
They are a population of immune cells that the WEHI researchers studied for their ability to recognize and attack small cell lung cancer. In the reported experiments, they killed cancer cells in patient-derived laboratory tumor models.
Did the study show that the drugs cure small cell lung cancer?
No. The study report describes increased cancer-cell killing in laboratory models when tarlatamab and zoledronate were used to strengthen gamma delta T-cell activity. It does not report a cure or demonstrate improved patient outcomes from this combination.
Why is small cell lung cancer difficult to treat with immunotherapy?
According to the report, SCLC can evade immune surveillance by conventional immune cells that many immunotherapy treatments rely on. The researchers are investigating gamma delta T cells as a possible alternative route for immune recognition.
Could this become a treatment for patients?
Possibly, but that has not been established. The researchers say the findings could inform cell-transfer strategies and further testing of existing medicines. Clinical studies would be needed to determine safety and benefit for patients.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
